Search

Your search keyword '"Pua, Uei"' showing total 2 results
Start Over Author "Pua, Uei" Publication Type Electronic Resources

Refine your results

2 results on '"Pua, Uei"'

1. Emerging Indications for Interventional Oncology: Expert Discussion on New Locoregional Treatments

Author

Iezzi, Roberto, Gangi, Afshin, Posa, Alessandro, Pua, Uei, Liang, Ping, Santos, Ernesto, Kurup, Anil N, Tanzilli, Alessandro, Tenore, Lorenzo, De Leoni, Davide, Filippiadis, Dimitrio, Giuliante, Felice, Valentini, Vincenzo, Gasbarrini, Antonio, Goldberg, Shraga N, Meijerink, Martijn, Manfredi, Riccardo, Kelekis, Alexi, Colosimo, Cesare, Madoff, David C, Iezzi, Roberto (ORCID:0000-0002-2791-481X), Giuliante, Felice (ORCID:0000-0001-9517-8220), Valentini, Vincenzo (ORCID:0000-0003-4637-6487), Gasbarrini, Antonio (ORCID:0000-0002-7278-4823), Manfredi, Riccardo (ORCID:0000-0002-4972-9500), Colosimo, Cesare (ORCID:0000-0003-3800-3648), Iezzi, Roberto, Gangi, Afshin, Posa, Alessandro, Pua, Uei, Liang, Ping, Santos, Ernesto, Kurup, Anil N, Tanzilli, Alessandro, Tenore, Lorenzo, De Leoni, Davide, Filippiadis, Dimitrio, Giuliante, Felice, Valentini, Vincenzo, Gasbarrini, Antonio, Goldberg, Shraga N, Meijerink, Martijn, Manfredi, Riccardo, Kelekis, Alexi, Colosimo, Cesare, Madoff, David C, Iezzi, Roberto (ORCID:0000-0002-2791-481X), Giuliante, Felice (ORCID:0000-0001-9517-8220), Valentini, Vincenzo (ORCID:0000-0003-4637-6487), Gasbarrini, Antonio (ORCID:0000-0002-7278-4823), Manfredi, Riccardo (ORCID:0000-0002-4972-9500), and Colosimo, Cesare (ORCID:0000-0003-3800-3648)

Abstract

Simple Summary Interventional oncology provides minimally invasive alternatives to many traditional medical and surgical treatments, offering a potential cure, control, or palliative care for many types of cancer patients. The aim of this article is to comprehensively review new indications for locoregional interventional oncology treatments and summarize the expert discussion and report from the "MIOLive Meets SIO" (Society of Interventional Oncology) session during the last Mediterranean Interventional Oncology Live congress held in Rome, Italy. Interventional oncology (IO) employs image-guided techniques to perform minimally invasive procedures, providing lower-risk alternatives to many traditional medical and surgical therapies for cancer patients. Since its advent, due to rapidly evolving research development, its role has expanded to encompass the diagnosis and treatment of diseases across multiple body systems. In detail, interventional oncology is expanding its role across a wide spectrum of disease sites, offering a potential cure, control, or palliative care for many types of cancer patients. Due to its widespread use, a comprehensive review of the new indications for locoregional procedures is mandatory. This article summarizes the expert discussion and report from the "MIOLive Meet SIO" (Society of Interventional Oncology) session during the last MIOLive 2022 (Mediterranean Interventional Oncology Live) congress held in Rome, Italy, integrating evidence-reported literature and experience-based perceptions. The aim of this paper is to provide an updated review of the new techniques and devices available for innovative indications not only to residents and fellows but also to colleagues approaching locoregional treatments.

Published
2023

2. Consensus Guidelines for the Definition of Time-to-Event End Points in Image-guided Tumor Ablation: Results of the SIO and DATECAN Initiative.

Author

Puijk, Robbert S. Ahmed, Muneeb Adam, Andreas Arai, Yasuaki Arellano, Ronald de Baère, Thierry Bale, Reto Bellera, Carine Binkert, Christoph A. Brace, Christopher L. Breen, David J. Brountzos, Elias Callstrom, Matthew R. Carrafiello, Gianpaolo Chapiro, Julius de Cobelli, Francesco Coupé, Veerle M. H. Crocetti, Laura Denys, Alban Dupuy, Damian E. Erinjeri, Joseph P. Filippiadis, Dimitris Gangi, Afshin Gervais, Debra A. Gillams, Alice R. Greene, Tissy Guiu, Boris Helmberger, Thomas Iezzi, Roberto Kang, Tae Wook Kelekis, Alexis Kim, Hyun S. Kröncke, Thomas Kwan, Sharon Lee, Min Woo Lee, Fred T. Lee, Edward W. Jr Liang, Ping Lissenberg-Witte, Birgit I. Lu, David S. Madoff, David C. Mauri, Giovanni Meloni, Maria Franca Morgan, Robert Nadolski, Gregory Narayanan, Govindarajan Newton, Isabel Nikolic, Boris Orsi, Franco Pereira, Philippe L. Pua, Uei Rhim, Hyunchul Ricke, Jens Rilling, William Salem, Riad Scheffer, Hester J. Sofocleous, Constantinos T. Solbiati, Luigi A. Solomon, Stephen B. Soulen, Michael C. Sze, Daniel Uberoi, Raman Vogl, Thomas J. Wang, David S. Wood, Bradford J. Goldberg, S. Nahum Meijerink, Martijn R. and Puijk, Robbert S. Ahmed, Muneeb Adam, Andreas Arai, Yasuaki Arellano, Ronald de Baère, Thierry Bale, Reto Bellera, Carine Binkert, Christoph A. Brace, Christopher L. Breen, David J. Brountzos, Elias Callstrom, Matthew R. Carrafiello, Gianpaolo Chapiro, Julius de Cobelli, Francesco Coupé, Veerle M. H. Crocetti, Laura Denys, Alban Dupuy, Damian E. Erinjeri, Joseph P. Filippiadis, Dimitris Gangi, Afshin Gervais, Debra A. Gillams, Alice R. Greene, Tissy Guiu, Boris Helmberger, Thomas Iezzi, Roberto Kang, Tae Wook Kelekis, Alexis Kim, Hyun S. Kröncke, Thomas Kwan, Sharon Lee, Min Woo Lee, Fred T. Lee, Edward W. Jr Liang, Ping Lissenberg-Witte, Birgit I. Lu, David S. Madoff, David C. Mauri, Giovanni Meloni, Maria Franca Morgan, Robert Nadolski, Gregory Narayanan, Govindarajan Newton, Isabel Nikolic, Boris Orsi, Franco Pereira, Philippe L. Pua, Uei Rhim, Hyunchul Ricke, Jens Rilling, William Salem, Riad Scheffer, Hester J. Sofocleous, Constantinos T. Solbiati, Luigi A. Solomon, Stephen B. Soulen, Michael C. Sze, Daniel Uberoi, Raman Vogl, Thomas J. Wang, David S. Wood, Bradford J. Goldberg, S. Nahum Meijerink, Martijn R.

Abstract

There is currently no consensus regarding preferred clinical outcome measures following image-guided tumor ablation or clear definitions of oncologic end points. This consensus document proposes standardized definitions for a broad range of oncologic outcome measures with recommendations on how to uniformly document, analyze, and report outcomes. The initiative was coordinated by the Society of Interventional Oncology in collaboration with the Definition for the Assessment of Time-to-Event End Points in Cancer Trials, or DATECAN, group. According to predefined criteria, based on experience with clinical trials, an international panel of 62 experts convened. Recommendations were developed using the validated three-step modified Delphi consensus method. Consensus was reached on when to assess outcomes per patient, per session, or per tumor; on starting and ending time and survival time definitions; and on time-to-event end points. Although no consensus was reached on the preferred classification system to report complications, quality of life, and health economics issues, the panel did agree on using the most recent version of a validated patient-reported outcome questionnaire. This article provides a framework of key opinion leader recommendations with the intent to facilitate a clear interpretation of results and standardize worldwide communication. Widespread adoption will improve reproducibility, allow for accurate comparisons, and avoid misinterpretations in the field of interventional oncology research. Published under a CC BY 4.0 license. Online supplemental material is available for this article. See also the editorial by Liddell in this issue.

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results